Novartis AG to acquire Exellergy for $2 billion, expand allergy portfolio
Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.
Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.
HQ Staff writer March 26, 2026: Deep in the sun-scorched lands of northern Kenya, where temperatures soar and water sources vanish for months
Merck & Co will buy Terns Pharmaceuticals, Inc., a clinical-stage oncology company, for $6.7 billion to pocket an investigational drug to treat a
HQ Team March 25, 2026: Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) mid-stage trials, held in China, helped in reducing
HQ Team March 25, 2026: Pfizer Inc. and France-based Valneva SE‘s investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals
Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for
Novartis AG has agreed to buy an investigational oral medicine of Pikavation Therapeutics, a subsidiary of privately-held Synnovation Therapeutics, to treat breast cancer, for
Switzerland’s F. Hoffmann-La Roche AG upgraded its artificial intelligence infrastructure by deploying Nvidia’s technology to accelerate development of diagnostic solutions and therapeutics.
About 4.9 million children died before their fifth birthday in 2024, including 2.3 million newborns, according to a UN report.
HQ Staff Writer March 17, 2026 : Public health officials in the United Kingdom are racing to contain a fatal outbreak of meningitis B in